Zoetis Inc. (ETR:ZOE)
122.56
-1.90 (-1.53%)
Sep 17, 2025, 9:04 AM CET
Zoetis Revenue
Zoetis had revenue of $2.46B USD in the quarter ending June 30, 2025, with 4.19% growth. This brings the company's revenue in the last twelve months to $9.39B, up 5.27% year-over-year. In the year 2024, Zoetis had annual revenue of $9.26B with 8.33% growth.
Revenue (ttm)
$9.39B
Revenue Growth
+5.27%
P/S Ratio
6.90
Revenue / Employee
$680.07K
Employees
13,800
Market Cap
55.18B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Sartorius Aktiengesellschaft | 3.47B |
Fresenius Medical Care AG | 19.52B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Zoetis News
- 1 day ago - Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors - Nasdaq
- 2 days ago - January 2028 Options Now Available For Zoetis (ZTS) - Nasdaq
- 2 days ago - Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain - Nasdaq
- 5 days ago - Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy - GuruFocus
- 5 days ago - Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats - Business Wire
- 8 days ago - Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News - GuruFocus
- 8 days ago - Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Top 50 High-Quality Dividend Stocks For September 2025 - Seeking Alpha